Exhibit 99.1 For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com INTERIM STATEMENT 9M 2022 HIGHLIGHTS EVOTEC'S TOPLINE SUCCESS REFLECTS STRONG OVERALL DEMAND SHARED R&D PLATFORMS FOR HIGHER PROBABILITIES OF SUCCESS (POS) 2 4 MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS 4 PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY 4 COMMERCIAL LAUNCH OF NEXT-GENERAT ...

Evotec SE (OTCPK:EVOTF) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants | --- | |------------------------------------------------| | | | Dr. Werner Lanthaler - Chief Executive Officer | | Enno Spillner - Chief Financial Officer | | Cord Dohrmann - Chief Scientific Officer | | Craig Johnstone - Chief Operating Officer | | Matthias Evers - Chief Business Officer | | Conference Call Participants | | | | Zoe Karamanoli - RBC Capital Markets | | James Quigley - Morgan Stanley | | ...

| --- | --- | |---------------------------------------------------|-------| | | | | Accelerating precision medicine | | | Evotec SE, H1 2022 Interim Report, 11 August 2022 | | Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "b ...

Exhibit 99.1 volker.braun@evotec.com, T. +49.(0)40.560 81-775, M. +49.(0)151.1940 5058, www.evotec.com #RESEARCHNEVERSTOPS HALF-YEAR REPORT 2022 Half-year Interim Report PUBLICATION DATE: 11 AUGUST 2022 -- For further information, please contact: Volker Braun, SVP Head of Global Investor Relations & ESG, HALF-YEAR REPORT 2022 I. MANAGEMENT REPORT 4 NEW AND EXTENDED ALLIANCES UNDERLINE SUCCESS OF GROWTH STRATEGY 4 ACQUISITION EXPANDS CAPABILITIES AND EXPERTISE IN CELL THERAPY 4 GUIDANCE FOR FULL-YEAR 2022 RE ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ Form 20-F ___________________________ (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition p ...

Evotec SE (NASDAQ:EVO) Q4 2021 Earnings Conference Call April 12, 2022 8:00 AM ET Company Participants Werner Lanthaler - Chairman and Chief Executive Officer Cord Dohrmann - Chief Scientific Officer Craig Johnstone - Chief Operating Officer Enno Spillner - Chief Financial Officer Conference Call Participants James Quigley - Morgan Stanley Joseph Hedden - Rx Securities Falko Friedrichs - Deutsche Bank Igor Kim - Berenberg Michael Ryskin - Bank of America Zoe Karamanoli - RBC Capital Markets Operator Dear la ...

Evotec SE (OTCPK:EVOTF) Q2 2021 Results Earnings Conference Call August 11, 2021 8:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright & Co. Joseph Hedden - Rx Securities Falko Friedrichs - Deutsche Bank Christian Ehmann - Warburg Research Victoria English - MedNous Operator Dear, ladies and gentlemen, welcome to the conference call of Evotec SE. At our customer's request, this c ...

Financial Performance H1 2021 - Group revenues increased by 17% to €2713 million (H1 2020: €2310 million), with organic growth at a record level of 27%[11] - Adjusted Group EBITDA decreased by 23% to €362 million (H1 2020: €473 million), mainly due to planned capacity build-up ahead of the imminent production start of J·POD® 1 US, like-for-like growth was 13%[11] - Expenses for unpartnered R&D increased by 29% to €278 million (H1 2020: €216 million)[11] - Net income increased significantly by over 100% to €1127 million (H1 2020: €73 million), benefiting from the fair value adjustment of EVO equity investment Exscientia[18] - Base revenues increased by 17% or €381 million to €2613 million, with Just – Evotec Biologics adding revenues of €230 million, an increase of 44%[20] Guidance and Outlook - The company confirmed its 2021 outlook, projecting Group revenues of €550-570 million (2020: €5009 million) and adjusted Group EBITDA of €105-120 million (2020: €1066 million)[11] - Unpartnered R&D expenses are expected to be €50-60 million (2020: €464 million)[11] - Action Plan 2025 targets were confirmed, aiming for revenues > €1000 million, adjusted EBITDA ≥ €300 million, and unpartnered R&D > €100 million[11] Strategic Developments - The acquisition of the Verona site from GlaxoSmithKline SpA was completed, now named "Campus Levi-Montalcini"[10, 35, 37] - A significant extension of the BMS Oncology protein degradation partnership was achieved ahead of term, along with a new protein degradation collaboration in an undisclosed therapeutic area also signed with BMS[10, 46] - J·POD® 1 US in Redmond is opening on August 18th, and construction of J·POD® 2 EU is set to start in Q4 2021[10] - The company submitted a registration statement for a proposed offering of American Depositary Shares (after period-end)[10]

Evotec SE (OTCPK:EVOTF) Q1 2021 Earnings Conference Call May 11, 2021 8:00 AM ET Company Participants Werner Lanthaler - CEO Enno Spillner - CFO Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright & Co. Christian Ehmann - Warburg Research Falko Friedrichs - Deutsche Bank Charles Weston - RBC Capital Markets Victoria English - MedNous Joseph Hedden - Rx Securities Limited Alex Cogut - Kempen & Co. Naresh Chouhan - Intrinsic Health Advisors Operator Dear ladies and gentlemen, welcome to the c ...

H PECCAACUNGVERJIVIN Accelerating on the data- driven Autobahn to Cures 【】【】【【】【 Evotec SE, First quarter 2021 results, 11 May 2021 Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate", "believe", "could", "estimate", "expect", "goa ...